Codetta Bio, Inc.

SAN DIEGO, April 28, 2025 /PRNewswire/ -- CS Genetics, a leader in single cell genomics, is proud to announce the appointment of Paul McEwan as an Independent Director to its Board. Mr. McEwan brings over two decades of experience in life science tools, genomics, and strategic growth. Mr. McEwan is a serial entrepreneur in the life sciences sector, with a proven track record of founding and scaling innovative biotech companies. He co-founded Kapa Biosystems, serving as Chief Scientific Officer from 2006 until its acquisition by Roche in 2015. Under his leadership, Kapa Biosystems pioneered the use of directed evolution to develop high-performance reagents for life science applications. In addition to Kapa Biosystems, Mr. McEwan co-founded Agencourt Bioscience and Agencourt Personal Genomics. These ventures collectively achieved an exit value of over $700 million, underscoring his ability to generate significant commercial and financial returns from venture-stage life-science companies. Beyond his entrepreneurial ventures, Mr. McEwan is an active angel investor, focusing on early-stage companies in life science tools and diagnostics. He currently serves as Chairman of DNA Script and SeqWell, and as a Board Member of Watchmaker Genomics, Oligo Factory and Codetta Bio. "We are thrilled to welcome Paul to our Board of Directors," said Bill Colston, CEO of CS Genetics. "His extensive experience in genomics and strategic growth will be invaluable as we continue to advance our mission of democratizing single cell genomics." About CS Genetics CS Genetics is a privately held genomics-technology company based in San Diego, California. The company has developed a radically new, instrument-free platform for single-cell genomics with disruptive simplicity, speed, and scalability that will launch a new era of NGS-based cellular analysis. The company's technology leverages a molecular process known as Kinetic Confinement that is categorically different to other single cell technologies, and plugs seamlessly into standard, widespread lab infrastructure. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, visit . Media Contact: Matt Browning Director of Marketing CS Genetics, Inc. [email protected] SOURCE CS Genetics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Corriveau brings 25 years of commercial and operational leadership experience in life sciences, biopharma, and diagnostics from Ultivue, AstraZeneca, Roche and NanoString DURHAM, N.C.--(BUSINESS WIRE)-- Codetta Bio, the life sciences company developing advanced multi-omic biomarker measurement tools, announced today that Jacques Corriveau has been appointed as its new Chief Executive Officer. In this role, Corriveau will lead Codetta’s next phase of commercial growth as the team advances the development of its disruptive multi-omic solution and brings its technology to market. This press release features multimedia. View the full release here: Jacques Corriveau, CEO at Codetta Bio (Graphic: Business Wire) Corriveau joins Codetta with more than 25 years of commercial and operational leadership in life science tools, biopharma, and diagnostics, and has demonstrated success in developing and growing early-stage companies. Most recently, Corriveau served as President and CEO at Ultivue, Inc. for three years, where he led organizational growth in commercial operations and manufacturing capacity. Prior to that, he worked for AstraZeneca’s Definiens Inc. as Vice President and General Manager for North America. Corriveau also spent 10 years in various commercial roles at NanoString Technologies, where he created, developed, and executed go-to-market strategies. “I was drawn to Codetta because of the potential its technology has to enable new assays at a scale and plex that I believe will rival next-generation sequencing without the expense and complexity,” said Corriveau. “Codetta’s mission perfectly aligns with my goal to make a meaningful contribution to establishing precision medicine as the universal standard of care.” Dr. Anthony Lemmo, who served as Codetta’s CEO for the last year, will continue to support the development and commercialization of the company’s breakthrough multi-omic biomarker measurement technology as Chief Technology Officer. “During my time as CEO, I was privileged to lead the company in developing a unique technology that I believe will uncover valuable information on diseases and help advance the research and development of new therapies. Jacques is enthusiastic, shares the same vision, and has the leadership skills Codetta needs to bring our innovative multi-omic solution to market,” said Dr. Lemmo. “I am excited to see Codetta advance to its next stage and look forward to supporting Jacques and the team in executing Codetta’s mission as CTO.” To learn more about Codetta Bio, please visit . About Codetta Bio Codetta Bio is developing advanced multi-omic biomarker measurement tools supporting data-driven approaches to understanding the unique genetic, environmental, lifestyle, and clinical factors that contribute to individual health and wellness. For more information, visit .

New funding will allow Codetta and NCCU to advance COVID related research and future clinical care MORRISVILLE, N.C.--(BUSINESS WIRE)-- Codetta® Biosciences, the life sciences company advancing and expanding research and diagnostic capabilities with its fully integrated, multi-omic platform, announced today that the North Carolina Collaboratory has awarded Codetta and North Carolina Central University (NCCU) a $2 million research and development grant, aimed to dramatically impact COVID related research and future clinical care. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, persists as a challenging world health crisis. Prevention, diagnosis, and treatment hinge on the ability to effectively detect SARS-CoV-2 and related health implications effectively and efficiently. Therefore, Codetta and the NCCU Advanced Center for COVID-19 Related Disparities (ACCORD) will collaborate to make technologies for detection of COVID and assessment of COVID related health issues more accessible and efficient. The Research Triangle Park, North Carolina based start-up is developing an integrated platform of reagents, hardware, and software designed to enable highly multiplexed, quantitative, simultaneous multi-omic analyses. In collaboration with NCCU, Codetta will use the funding from the North Carolina Collaboratory to enable detection of a panel of respiratory infectious diseases, as well as severity of host response and potential impact of long-COVID. “We are privileged to be collaborating with Dr. Deepak Kumar and colleagues at NCCU ACCORD,” said TJ Johnson, CEO at Codetta. “This initiative directly aligns with Codetta’s purpose, to bring highly-complex medical and non-medical molecular testing to people and places everywhere.” The North Carolina Collaboratory awarded NCCU and Codetta the grant through their Business-Academic Partnership Program, aimed to address the public health and economic impacts of COVID-19 in North Carolina. “The ability to research and diagnose infections with clinically similar presentation to COVID-19 and rapidly identify those at high risk for more serious health implications, both short and long term, will provide a powerful tool to bring improved health care across North Carolina and beyond,” said Dr. Deepak Kumar, Principal Investigator at NCCU. “We’re looking forward to collaborating with Codetta to uncover new information about this disease and make testing more accessible to all.” For more information, visit . About Codetta® Biosciences Codetta® Biosciences’ mission is to advance and expand life science research and diagnostic capabilities by providing an easy-to-use, streamlined multi-omic testing solution. The company is developing and plans to commercialize a novel, fully integrated, multi-omic platform (instrument, software, consumables, with data analytics) that will set a new standard of multi-omic performance and simplicity, making this capability accessible to all researchers in commercial and diagnostic labs at a significantly lower price point than its current competitors. With this platform, Codetta aims to advance the research and development of next-generation therapies, and ultimately improve patient care and quality of life. For more information, visit . About North Carolina Central University (NCCU) North Carolina Central University (NCCU) prepares students to succeed in the global marketplace. Consistently ranked as a top Historically Black College or University, NCCU’s flagship programs in the sciences, education, law, business, nursing and the arts prepare students for professions ranging from clinical research to information science. Founded in 1910, NCCU remains committed to diversity in and access to higher education. With a mission to investigate health disparities, the university’s two state-of-the-art research institutes give students real-world experience working alongside faculty researchers and pharmaceutical and biotechnology industry professionals. The university’s Strategic Plan 2019-2024, Charting a New Landscape for Student-Center Success, focuses on four areas: student access and success; innovation, research and entrepreneurship; collaboration and partnerships; and institutional sustainability. Visit .